1. Introduction {#sec1-molecules-23-01622}
===============

Inflammatory bowel disease (IBD) includes two major types of disease: Crohn's disease (CD) and ulcerative colitis (UC) \[[@B1-molecules-23-01622],[@B2-molecules-23-01622]\], which are chronic recurrent inflammatory diseases of the gastrointestinal tract involving the large intestine or colon \[[@B3-molecules-23-01622]\]. UC and CD are considered different conditions; however, they share some common clinical features, such as cycles of relapse and remitting mucosal inflammation \[[@B4-molecules-23-01622]\]. For UC, the inflammation is restricted to the colon and rectum continuously, with some cases even reaching the whole colon. Ulcerative colitis is one of the most common causes of colorectal cancer. Carcinogenesis is related to the time limit and extent of lesions of ulcerative colitis. The longer the disease course, the greater the chance of carcinogenesis in active cases with more extensive lesions. The incidence of ulcerated colorectal cancer is significantly higher than that of the general population. In the process of inflammatory hyperplasia, inflammatory or pseudopolyps are often formed and cancer occurs. However, it takes a long time and the cancerous rate of this colonic polyp is low. The occurrence of cancerous changes in the karyotype is more common in the undifferentiated type, with a higher degree of malignancy and a poorer prognosis \[[@B5-molecules-23-01622]\]. CD affects any region of the GI tract, with the terminal ileum and the colon commonly affected, and the inflammation is generally noncontinuous \[[@B6-molecules-23-01622],[@B7-molecules-23-01622]\]. The exact cause of IBD is uncertain, but some factors have been suggested, such as immunological, genetic and environmental \[[@B8-molecules-23-01622]\].

The cause and cure for IBD are yet to be discovered, and therapeutic strategies are aimed towards attaining and maintaining remission from inflammatory episodes. Intestinal mucosa of patients with IBD has been previously reported and is characterized by overproduction of reactive oxygen species (ROS) and an imbalance of important antioxidants, leading to oxidative damage. Self-sustaining cycles of oxidant production may amplify inflammation and mucosal injury \[[@B7-molecules-23-01622],[@B8-molecules-23-01622]\]. Thus, the main goal of IBD treatment is to prevent frequent recurrence of inflammation and maintain remission. Nonenzymatic therapies include drugs classified as aminosalicylate, corticosteroids, immunosuppressive agents and biological agents. Corticosteroids such as synthetic prednisone are still the most effective treatment in activated stage of IBD. These steroids act on the immune response in a wide range of ways, and patients often have long-term dependence on these drugs. 5-aminosalicylic acid (5-ASA) preparations such as mesalamine and the like are widely used for remission treatment. Chemotherapy can be administered by using azathioprine (AZA), its metabolite 6-mercaptopurine (6-MP) and methotrexate. Antibiotics such as metronidazole or ciprofloxacin are used in IBD to treat intestinal infections caused by high bacterial load (Bacteroides, Clostridium difficile). Although many patients are successfully treated with conventional medications (most relief), two-thirds require surgery. Further treatment strategies for IBD that target long-term treatment of lymphocytes and inflammatory cytokines have been designed and under investigation. Traditionally, drugs mediating these desired effects, such as salicylic acid, glucocorticoid, immunosuppressive agents, immune modulators, and other conventional drugs \[[@B9-molecules-23-01622]\], are usually administered in high doses and/or systemically, leading to significant adverse events. Therefore, the prevention and reduction of drug-related side effects are highly challenging in IBD treatment \[[@B10-molecules-23-01622]\].

The oral dosage form is characterized by low production cost, easy handling for the patient, accurate dose, and excellent stability and storage. In contrast, the oral route is affected by changes in intestinal absorption, metabolism of the intestinal cells, and usually the liver is encountered in the portal circulation, thereby passing the first-pass effect. In general, the oral route is the most desirable and acceptable route for administering drugs in the treatment of IBD \[[@B11-molecules-23-01622]\]. After oral formulations are administered, the dosage forms release the active ingredients into the intestinal lumen where they are absorbed by the gastrointestinal mucosa. Finally, the active ingredient reaches the systemic circulation and is distributed throughout the body. However, systemic adverse drug reactions may also occur and may affect the quality of life of patients. The marked differences in the intestinal tract environment of the gastrointestinal tract and the differences between the healthy and inflamed intestinal regions have facilitated the development of pharmaceutical technologies that specifically deliver the active compounds to the inflamed intestinal regions. Oral drug-delivery systems for the treatment of IBD have been developed and allow more or less effective delivery of drugs to the site of disease. Based on the persistent large intestine in UC, most oral dosage forms are used to treat the colon. Therefore, it is much more difficult to treat discrete areas of inflammation in the CD by using an oral drug-delivery system \[[@B12-molecules-23-01622]\].

Targeting preparations could improve pharmacological effects and reduce adverse reactions \[[@B13-molecules-23-01622]\]. Targeted drug delivery can be divided based on carriers. These include liposomes, microparticles, nanoparticles and emulsions. Among recent techniques used for colon-specific delivery, micro- and nanoparticles are well known for achieving site specificity and increasing drug stability via encapsulation \[[@B14-molecules-23-01622]\]. The main objective of targeted drug strategy is to target the maximum concentration of active agents in inflamed intestinal tissues by using selective delivery to achieve therapeutic efficacy, while simultaneously reducing adverse effects. In addition, such a targeted delivery system must meet the conditions for complete biodegradation and high biocompatibility without pro-inflammatory properties \[[@B15-molecules-23-01622]\]. Nanotherapeutics \[[@B16-molecules-23-01622],[@B17-molecules-23-01622]\], therapeutic targets \[[@B18-molecules-23-01622]\] and colon-targeted oral drug-delivery systems \[[@B19-molecules-23-01622]\] for inflammatory bowel disease have been reviewed. In our review, new targeting preparations in IBD therapy are systematically reviewed. The structural diagram of these oral colon-targeted delivery systems is shown in [Figure 1](#molecules-23-01622-f001){ref-type="fig"}. This paper provides a valuable pharmaceutical strategy for studying the formula and preparation technology of oral colon-targeted delivery systems that are suitable for treating IBD.

2. Pharmaceutical Strategies {#sec2-molecules-23-01622}
============================

2.1. Liposomes {#sec2dot1-molecules-23-01622}
--------------

Liposomes are double-layer vesicle structures based on phospholipids that are enclosed in aqueous volumes. Liposomes exhibit highly compatible phospholipid vesicles that are capable of carrying hydrophilic (aqueous core) and lipophilic (in lipid bilayer) medicaments due to their amphoteric properties. A lipophilic drug is incorporated in the liposome at the same time the lipid membrane is formed, and the hydrophilic drug is dissolved in the aqueous medium. The lipid membrane is hydrated by continuous rotation, extrusion, sonication or other ways to form vesicles. These systems are designed using a controlled delivery system, but the system must be targeted and protected from changes in pH \[[@B20-molecules-23-01622]\]. Liposomes, which are biodegradable and essentially nontoxic vehicles, can encapsulate both hydrophilic and hydrophobic materials \[[@B21-molecules-23-01622]\]. The use of liposomes has been shown to selectively target inflamed tissues, with the disruption of the intestinal barrier function at the site of inflammation, allowing accumulation of particulate delivery carriers. Liposomes can also be modified to enhance binding and cellular uptake to diseased tissue with the use of cationic lipids or attachment of targeting ligands \[[@B22-molecules-23-01622]\].

L. Li and his colleagues evaluated the preclinical antitumor activity of liposomal curcumin in colorectal cancer. In this study, the efficacy of liposomal curcumin with standard chemotherapeutic agents (oxaliplatin) was compared. Different ratios of total lipid to curcumin (*w/w*) were evaluated from 10:1 to 4:1. The optimized 10:1 ratio was selected based on the test to determine the optimal encapsulation efficiency of curcumin by the liposomes. In-vitro studies with curcumin liposomes and dose-dependent growth inhibition were observed, and apoptosis in LoVo and Colo205 human colorectal cancer cell lines was observed. Synergy was also observed in in-vitro LoVo cells with a 4:1 ratio of liposomal curcumin and oxaliplatin. In-vivo studies also showed significant tumor growth inhibition in Colo205 and LoVo cells, and the growth inhibition observed with liposome curcumin was higher in Colo205 cells than oxaliplatin. Antiangiogenic effects are seen when tumors from animals are treated with liposomal curcumin. By immunohistochemical observation of CD31, the expression of vascular endothelial growth factor and interleukin-8 was attenuated. Therefore, curcumin liposomes exhibit better in-vitro and in-vivo activity in colorectal cancer \[[@B23-molecules-23-01622],[@B24-molecules-23-01622]\].

2.2. Nanoparticles {#sec2dot2-molecules-23-01622}
------------------

Granular carriers are small carrier-based lipids and polymer matrix systems, where the drug is dispersed or dissolved in a lipid or polymer matrix. These systems are called nanoparticles or microparticles, based on size. Nanoparticles (NPs) in nanoscale units consist of two types: solid lipid nanoparticles and nanostructured lipid particles. Microparticles, on the other hand, are usually micron-sized microspheres. In order to increase the efficacy of IBD treatment, these particle systems can be further modified by coating or encapsulating with alginate beads. This matrix system prevents rapid drug release and promotes controlled release by reducing mobility of the drug molecules bound to the solid matrix. The release of the drug in the matrix system is further influenced by matrix composition and particle structure \[[@B25-molecules-23-01622]\]. NPs, with a diameter of 10--1000 nm, are drug-loaded particles that are prepared by taking natural polymers or synthetic chemicals as carriers. Drugs can be embedded or dissolved in NPs and adsorbed or coupled on their surface. Encapsulating drugs within NPs can improve the solubility and pharmacokinetics of drugs and, in some cases, enable further clinical development of new chemical entities that have stalled because of poor pharmacokinetic properties \[[@B26-molecules-23-01622]\].

Solid lipid NPs (SLNs) are beneficial in terms of drug protection and prevention of degradation. As a result of the homogenization of SLNs, increase in entrapment efficiency and initial release results in an increase in the bioavailability of the encapsulated drug. Due to the slow degradation of the lipid matrix, SLNs have unique properties, such as micro size with high surface area, high drug-loading capacity, and extended drug release. These systems are typically prepared by applying high-pressure homogenate and ultrasonic treatment of molten lipids. Some NP carriers for the treatment of IBD are based on chitosan, poly (lactic-co-glycolic acid) (PLGA), Eudragit P-4135F, which is a new pH-sensitive polymer, and silica NPs \[[@B27-molecules-23-01622]\]. Nanostructured lipid carriers (NLCs) are part of the nanometer linear system. These systems are mixed with solid and liquid lipids. Liquid lipids provide flexibility in the carrier system, allowing for improved drug loading. The concept behind its preparation is that the solid lipid crystals with a higher melting point form a lipid core, and then the liquid lipid forms an outer layer containing a higher amount of lipophilic drug. Advantages of this structure include providing oxidation and hydrolytic stability \[[@B28-molecules-23-01622]\]. [Table 1](#molecules-23-01622-t001){ref-type="table"} shows the formula, preparation method and biological activity of different nanoparticles in treating UC.

2.3. Microparticles {#sec2dot3-molecules-23-01622}
-------------------

Microparticles (MPs) used in IBD therapy often range from 1--150 µm in diameter and are designed to target inflamed intestinal tissues and/or to be internalized by immune cells. The most common methods for MP fabrication include the complex coacervation method. This involves the emulsion solvent-evaporation approach, spray-drying process, and solvent-extraction method. MPs can be divided into noncoated and coated forms. Noncoated MPs can be characterized as a system that encapsulates the drug directly into polymers \[[@B49-molecules-23-01622]\]. [Table 2](#molecules-23-01622-t002){ref-type="table"} shows the formula, preparation method and biological activity of different microparticles in treating UC.

2.4. Self-Assembled Polymer System {#sec2dot4-molecules-23-01622}
----------------------------------

Self-assembled polymer systems consist of natural and synthetic polymers, which are oriented in specific shapes or forms, or swell in the presence of water or any suitable specific polar solvent system. These systems are commonly used in antifungal and topical forms to treat ulcers and cancers.

Hydrogels are crosslinked networks of hydrophobic polymers that are physically or chemically linked to each other. The system is expanded by absorbing large amounts of water, and the drug is released by swelling or by degradation of the polymer after swelling. The intestinal mucosal region acts as a hydrogel that provides effective control of release of the drug into the inflammatory site. Hydrogels can be classified as macroporous, microporous, or nonporous according to pore size formed by the entanglement of the polymer. The pore size of macroporous hydrogels is 0.1--1 μm. The microporous water gel pore is 100--1000 Å, and the nonporous hydrogel pore is 10--100 Å \[[@B66-molecules-23-01622]\].

In our previous study, we provided evidence for paeonol as a novel therapeutic agent in the treatment of UC, which was isolated from *Cynanchum paniculatum* (Bge.) Kitag. or *Aaeoina suffruticosa* Andr. in traditional Chinese medicine \[[@B67-molecules-23-01622]\]. We also developed satisfactory paeonol coating tablets with pH-time-delayed controlled release in the colon \[[@B68-molecules-23-01622],[@B69-molecules-23-01622]\]. Moreover, we prepared the colon-specific delivery system (Pae-SME-CSC) with paeonol-loaded self-microemulsion (Pae-SMEDDS), and evaluated its properties in vitro and in vivo, especially the anti-inflammatory effects on UC rats. It indicated that the developed Pae-SME-CSC was suitable for colon-specific drug delivery \[[@B70-molecules-23-01622]\].

2.5. Emulsion-Based Carrier {#sec2dot5-molecules-23-01622}
---------------------------

These carriers are formed by the dispersion of two or more immiscible liquids stabilized by a surfactant or an emulsifier. The emulsifier causes the liquid to disperse evenly into the continuous liquid medium and produce a physical exclusion between the droplets to avoid coalescence by coating the droplets and lowering the interfacial tension \[[@B71-molecules-23-01622]\].

Microemulsions are thermodynamically stable isotropic dispersions. The biphasic immiscible liquid is stabilized by the interfacial membrane of the surfactant molecule bound to the co-surfactant. The relative concentration of these three components can be estimated by constructing a ternary phase diagram. The components are oil in water (*o/w*) or water in oil (*w/o*), in the range of 5--100 nm. Microemulsions (*o/w* and *w/o*) improve the oral bioavailability of drugs. These have additional formulation advantages, thermodynamic stability, easy sterilization by filtration, small droplet size, and high surface area, which provide increased surface area for absorption and delivery of drug molecules. Release from the microemulsion is controlled by the interaction between the drug surfactant and the distribution of the drug between the oil phase and the aqueous phase. These systems can be highly developed for the treatment of internal inflammatory diseases \[[@B72-molecules-23-01622]\].

Nanoemulsions are a uniform population of particle droplets consisting of long-term thermodynamically stable lipids and surfactants. These droplets are usually composed of lipid monolayer surrounding the liquid lipid core. Nanoemulsions are prepared by high-pressure homogenization, which results in the formation of droplets of uniform size. Using nanoemulsions as a carrier system has already been studied for broad-spectrum antimicrobial activity against microorganisms. In-vivo studies reveal its efficacy for treating vaginal, fungal and respiratory infections against the skin and mucous membranes. Moreover, this may be effective in treating gastritis \[[@B73-molecules-23-01622]\].

2.6. Potential Therapeutic Approach {#sec2dot6-molecules-23-01622}
-----------------------------------

The complement system is widely considered to protect the host from invading microorganisms. However, previous studies examining the activation of the complement system have shown that it may play a detrimental role in the pathogenesis of many inflammatory and immune diseases. Complement activation products include complement components (C) 3a, C4a, C5a and C5b-9, and membrane-attack complexes. The complement activation product complement component 5a (C5a) is a potent inflammatory peptide with a broad spectrum of functions. In-vivo and in-vitro studies have demonstrated that C5a plays an important role in inflammation. Li Zhiping studied the role of C5a in IBD using an experimental mouse colitis model. Colitis was induced in mice using 2,4,6-trinitrobenzene sulphonic acid (TNBS), followed by administration of C5a aptamer by intraperitoneal injection. The clinical signs of the disease, the histopathological analysis of the colon and the level of inflammatory components were examined. Symptoms of colitis, including altered behavior, weight loss, colon damage and increased inflammatory cytokines, attenuated after treatment of mice with TNBS-induced colitis containing C5a aptamers. By phenotypic observation, histological examination and levels of inflammatory cytokines demonstrated that aptamer-treated mice exhibited significant colitis-attenuating effects compared to untreated mice. Colitis is characterized by an imbalance between proinflammatory and anti-inflammatory media. Current research results show that C5a may play a key role in IBD inflammation \[[@B74-molecules-23-01622]\].

3. Pharmacokinetic Studies {#sec3-molecules-23-01622}
==========================

Pharmacokinetics is used to evaluate pharmaceutical preparations for slow-release drug-delivery systems. First, studying pharmacokinetic properties allows us to understand the absorption, distribution, metabolism and excretion characteristics of drugs in the body. Related pharmacokinetic parameters, combined with the physical and chemical properties of drugs, pharmacodynamic properties and clinical needs, help determine drug preparation's necessity \[[@B75-molecules-23-01622]\]. During drug preparation into a sustained-release drug-delivery system, pharmacokinetic principles are used to design dosage form, dose, release mode, release time, and other factors. In addition, pharmacokinetic studies are used to evaluate and monitor whether the system achieves the desired effect of sustained drug release. In recent years, the development of modern instrumental analysis technology brought new technologies for pharmacokinetic studies. These include liquid chromatography, ion-selective electrode method, gas chromatography, mass spectrometry, and application of tandem mass spectrometry in the detection of drug concentration in chemical drugs by modern instrumental analysis methods \[[@B76-molecules-23-01622]\].

Ye Liu applied HPLC analysis using a Dikma Diamonsil C18 on a Shimadzu LC-20A HPLC system with an ultraviolet detector at room temperature. The wavelength of the ultraviolet detector was 245 nm. Water and ethanol (57:43 *v/v*) were used as the mobile phase at a flow rate of 1 mL/min. The prolongation of the half-life (t~1/2~), enhanced residence time (mean residence time, MRT), and decreased total clearance (CL) indicated that BUD microspheres could prolong the acting time of BUD in vivo \[[@B60-molecules-23-01622]\]. Srinivas Mutalik prepared novel pH-sensitive hydrolyzed polyacrylamide-grafted xanthan gum (PAAm-g-XG) nanoparticles (NPs) loaded with curcumin for colonic delivery. Curcumin was better absorbed systemically in nanoparticulate form with increased *C~max~* (3-fold) and AUC (2.5-fold) than when delivered as free curcumin \[[@B43-molecules-23-01622]\]. Hiraku Onishi prepared and evaluated simple Eudragit S100 microparticles loaded with prednisolone (ES-MP) and Eudragit S100-coated chitosan-succinyl-prednisolone conjugate microparticles (Ch-MP/ES) in vitro. It was demonstrated that Ch-MP/ES could enhance the efficacy of PD and reduce the toxic side-effect of PD, while ES-MP could hardly improve the effects of PD. Only Ch-MP/ES significantly changed in-vitro and in-vivo characteristics and was found to improve PD's in-vivo function \[[@B77-molecules-23-01622]\].

4. Conclusions {#sec4-molecules-23-01622}
==============

IBD is a chronic disease that has an immunization period when the disease is not active. Hence, most patients need to maintain drug therapy to relieve symptoms and shorten the number and severity of seizures \[[@B78-molecules-23-01622]\]. Treatment of IBD is minimal, but some drugs can reduce the severity of inflammation, increase the duration of remission, and reduce the risk of more serious health problems, such as colorectal cancer. Years of research have demonstrated the suitability of the colon as an absorption site, especially in GI diseases \[[@B79-molecules-23-01622]\]. Conventional drug-delivery systems rely primarily on several nonstable parameters in the gastrointestinal tract, such as changes in pH and local enzyme-induced drug release. New drug-delivery systems, particularly multiparticle systems such as microspheres and nanoparticles, exhibit higher drug-delivery capability due to their specific accumulation, spread and long-term retention in the target inflammatory tissue compared with conventional single-unit modes \[[@B80-molecules-23-01622]\]. Unfortunately, the problem associated with the nanoparticle process is it exhibits altered physical and chemical properties and potential risk of causing possible toxicity compared with its larger counterpart. Abiotic nanoparticle carriers can alter normal cellular activity and cause cytotoxicity because the particles cause wrinkling to the cell membrane, cytoskeleton rearrangement, and phagocytosis leading to their entry into phagocytic cells \[[@B81-molecules-23-01622]\]. Thus, biotechnology systems with fewer side effects may have great potential in future IBD treatments. A highly biological approach in IBD treatment with a drug-delivery system does not alter normal cellular function. This may be the best method to achieve satisfactory effects in IBD therapy. Although studies on the effects of new multiparticle systems in the human gastrointestinal tract during IBD treatment are limited and need further exploration, we see that these systems will be used in combination with new biological agents in the near future to achieve maximum targeted drug efficacy at lower drug doses and side effects due to their superior advantages, such as sustainability and controlled release.
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molecules-23-01622-t001_Table 1

###### 

Studies on the formula, preparation method and biological activity of different nanoparticles in treating ulcerative colitis (UC).

  Categories                            Carrier Materials                                                                                                 Pharmaceutical Ingredients                                                                           Preparation Methods                                                                    Biological Activity                                                                                                                                                         Ref.
  ------------------------------------- ----------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------
  Nanoparticles                         Polymethacrylate (Eudragit RL)                                                                                    Clodronate                                                                                           Modified solvent-displacement method                                                   Confirmed therapeutic benefit of ClNP in vivo                                                                                                                               \[[@B29-molecules-23-01622]\]
  Nanoparticles                         Poly (lactic acid) poly (ethylene glycol) block copolymer (PLA-PEG)                                               TNFα siRNA                                                                                           Double emulsion/solvent evaporation                                                    Powerful and efficient nanosized tools for delivering siRNAs into colonic macrophages                                                                                       \[[@B30-molecules-23-01622]\]
  Nanoparticles                         \-\--                                                                                                             Lipids, proteins, microRNAs (miRNAs), and ginger bioactive constituents (6-gingerol and 6-shogaol)   Derived from edible ginger                                                             Improve inflammatory bowel disease (IBD) prevention and treatment with an added benefit of overcoming limitations such as potential toxicity and limited production scale   \[[@B31-molecules-23-01622]\]
  Nanoparticles                         Polymeric mixtures of poly (lactic-co-glycolic) acid (PLGA)                                                       Budesonide                                                                                           Oil/water (*O/W*) emulsion-evaporation technique                                       An efficient delivery system for targeted drug delivery to the inflamed intestinal mucosa                                                                                   \[[@B32-molecules-23-01622]\]
  Nanoparticles                         PLGA 50:50                                                                                                        Betamethasone                                                                                        Oil-in-water solvent-evaporation method (simple oil/water emulsification technique)    Stable targeting moiety in the gastrointestinal tract                                                                                                                       \[[@B33-molecules-23-01622]\]
  Nanoparticles                         Eudragit FS30D, Eudragit RS100                                                                                    Budesonide                                                                                           Oil-in-water emulsion method                                                           An effective oral colon-targeted delivery system for colitis therapy                                                                                                        \[[@B34-molecules-23-01622]\]
  Nanocapsules                          Eudragit S100                                                                                                     Prednisolone                                                                                         Nanoprecipitation method                                                               Provide effective way of treatment of colonic disease                                                                                                                       \[[@B35-molecules-23-01622]\]
  Nanoparticles                         Polymeric mixtures of poly PLGA and a pH-sensitive methacrylate copolymer                                         Budesonide                                                                                           An adaption of the modified spontaneous emulsification solvent diffusion method        Useful for colon-specific delivery in inflammatory bowel disease                                                                                                            \[[@B36-molecules-23-01622]\]
  Nanoparticles                         PLGA                                                                                                              Budesonide                                                                                           Oil-in-water (*O/W*) emulsion technique                                                Targeted drug delivery to the inflamed intestinal mucosa                                                                                                                    \[[@B37-molecules-23-01622]\]
  Nanostructure lipid carriers (NLCs)   Precirol ATO^®^5, Miglyol 812                                                                                     Budesonide                                                                                           High-pressure homogenization                                                           A targeted drug-delivery system for IBD treatment                                                                                                                           \[[@B38-molecules-23-01622]\]
  Nanoparticles                         Trimethylchitosan (TMC) Eudragit^®^ S100 PLGA, PEG-PLGA and PEG-PCL                                               Ovalbumin (OVA)                                                                                      Water-in-oil-in-water solvent-evaporation method, ionic complexation/gelation method   The highest accumulation of ovalbumin (OVA) in inflamed colon                                                                                                               \[[@B10-molecules-23-01622]\]
  Nanoparticles                         PLA                                                                                                               CD98 Fab′-bearing quantum dots (QDs)                                                                 A modified oil-in-water (*O/W*) emulsion solvent-evaporation technique                 Active colitis-targeted delivery                                                                                                                                            \[[@B39-molecules-23-01622]\]
  Nanoparticles                         EC                                                                                                                Betamethasone                                                                                        Emulsification solvent-evaporation technique                                           A significantly higher mitigating effect                                                                                                                                    \[[@B40-molecules-23-01622]\]
  Nanoparticles                         Eudragit RL PO                                                                                                    Silybin                                                                                              Solvent-evaporation emulsification technique                                           Reduced TNF-a, IL-6 and MPO activity significantly                                                                                                                          \[[@B41-molecules-23-01622]\]
  Nanoparticles                         Enzyme-sensitive azo-polyurethane and pH-sensitive methacrylate copolymer                                         Budesonide                                                                                           A quasiemulsion solvent diffusion with some modifcations                               An effective and safe colon-targeted delivery system for colitis therapy                                                                                                    \[[@B42-molecules-23-01622]\]
  Nanoparticles                         Novel pH-sensitive hydrolyzed polyacrylamide-grafted xanthan gum (PAAm-g-XG)                                      Curcumin                                                                                             A modified version of the solvent-evaporation cross-linking technique                  Suitable for colon targeting                                                                                                                                                \[[@B43-molecules-23-01622]\]
  Silica nanoparticles (SiNPs)          Silica                                                                                                            5-Amino salicylic acid (5ASA)                                                                        \-\--                                                                                  Combine advantages from selective drug targeting and prodrugs                                                                                                               \[[@B44-molecules-23-01622]\]
  Nanoparticles                         Eudragit S100 (EU S100)                                                                                           5-Aminosalicylic acid (5-ASA)                                                                        Supercritical fluids (SEDS) technique                                                  5-ASA was imbedded into EU S100 in an amorphous state after SEDS processing and the SEDS process did not induce degradation of 5-ASA                                        \[[@B45-molecules-23-01622]\]
  Nanoparticles                         Oxidation-responsive b-cyclodextrin material (OxbCD)                                                              Tempol (Tpl)                                                                                         A modified nanoprecipitation/self-assembly method                                      Reduce ulcerative colitis in mice effectively                                                                                                                               \[[@B46-molecules-23-01622]\]
  Nanoparticles                         EudragitR S100                                                                                                    Curcumin--celecoxib combination                                                                      Emulsion solvent-evaporation technique                                                 More efficacious than nanoparticles of either drugs or drug suspension                                                                                                      \[[@B47-molecules-23-01622]\]
  Nanovesicles                          Hydrogenated soy phosphatidylcholine-coating polyethylene glycol-containing vesicles with chitosan and nutriose   Quercetin                                                                                            \-\--                                                                                  A marked amelioration of symptoms of 2,4,6-trinitrobenzenesulfonic acid-induced colitis                                                                                     \[[@B48-molecules-23-01622]\]

molecules-23-01622-t002_Table 2

###### 

Studies on the formula, preparation method and biological activity of different microparticles in treating UC.

  Categories             Carrier Materials                                                                                                    Loaded-Ingredients                                                Preparation Methods                                                         Biological Activity                                                                                                                                                    Ref.
  ---------------------- -------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------- --------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------
  Microsphere            Chitosan-alginate                                                                                                    Icariin                                                           Emulsification-internal gelation technique                                  Exert the colon-protective effects through reducing the inflammatory response                                                                                          \[[@B50-molecules-23-01622]\]
  Microsphere            Eudragit S100 liquid paraffin                                                                                        Metronidazole                                                     Emulsification solvent-evaporation method                                   Enhance drug entrapment, and effect the drug release                                                                                                                   \[[@B51-molecules-23-01622]\]
  Microsphere            PLGA microsphere                                                                                                     Glucagon-like peptide-2                                           Solid-in-oil-in-water (*S/O/W*) method                                      Resistant to degradation and decreased the severity of dextran sulfate sodium (DSS)-induced ulcerative colitis                                                         \[[@B52-molecules-23-01622]\]
  Microspheric vehicle   Microspheric vehicle formed by cationic konjac glucomannan (cKGM), phytagel                                          An antisense oligonucleotide against TNF-α                        Water-in-oil (*W/O*) emulsion method                                        Significantly decreased the local level of TNF-α and alleviated the symptoms of colitis in the mice                                                                    \[[@B53-molecules-23-01622]\]
  Microsphere            pH-triggered Eudragit-coated chitosan microspheres                                                                   Curcumin                                                          Emulsion crosslinking method followed by coating with Eudragit S-100        A promising system for pH-dependent delivery of drug to colon in ulcerative colitis                                                                                    \[[@B54-molecules-23-01622]\]
  Microsphere            The enzyme diamine oxidase (DAO) in CaCMS/alginate microspheres                                                      The enzyme diamine oxidase (DAO)                                  \-\--                                                                       A procedure able to afford protection of the entrapped enzyme against gastrointestinal degradation                                                                     \[[@B55-molecules-23-01622]\]
  Microsphere            Colon-targeted microspheres which were compressed into tablets using the enzyme-dependent polymer (pectin) as coat   The nonsteroidal anti-inflammatory bumadizone calcium dihydrate   Quasi-emulsion solvent-diffusion method                                     Achieved significant decrease in myeloperoxidase activity and inflammation with delayed T~max~ (4 h) and lower C~max~ (2700 ng/mL) when compared to marketed product   \[[@B56-molecules-23-01622]\]
  Microsphere            Hydrogel microspheres of chitosan grafted with vinyl polymers                                                        5-Aminosalicylic acid (5-ASA)                                     Water-in-oil (*W/O*) emulsification method                                  Exhibited better therapeutic effects in comparison to 5ASA plain drug solution in oral administration                                                                  \[[@B57-molecules-23-01622]\]
  Microsphere            Chitosan microspheres                                                                                                5-ASA and camylofine dihydrochloride                              Emulsion method followed by enteric coating with Eudragit^®^ S-100          Specific delivery of drug to the colon and reduce symptoms of ulcerative colitis                                                                                       \[[@B58-molecules-23-01622]\]
  Microsphere            Eudragit L100 (EuL)-coated chitosan (Ch)--succinyl-prednisolone (SP) conjugate microspheres (Ch SP-MS/EuL)           Prednisolone (PD)                                                 \-\--                                                                       Enhanced effectiveness of PD and reduced toxic side effects of PD greatly                                                                                              \[[@B59-molecules-23-01622]\]
  Microsphere            Budesonide (BUD) guar gum microspheres                                                                               Budesonide (BUD)                                                  Emulsion crosslinking technique                                             Prolong the acting time of BUD in vivo                                                                                                                                 \[[@B60-molecules-23-01622]\]
  Microsphere            Chitosan microparticles                                                                                              Mesalamine                                                        Emulsion chemical crosslinking technique                                    Maintain the drug concentration within target ranges for a long period of time                                                                                         \[[@B61-molecules-23-01622]\]
  Microparticle          Kafrin microparticles                                                                                                Prednisolone                                                      A phase-separation method                                                   The majority of the loaded prednisolone was not released in in-vitro conditions simulating the upper gastrointestinal tract                                            \[[@B62-molecules-23-01622]\]
  Microparticle          *N*-Succinyl-chitosan (SucCH) microparticle                                                                          5-ASA                                                             Spray-drying method                                                         Improved efficacy in the healing of induced colitis in rats                                                                                                            \[[@B63-molecules-23-01622]\]
  Microsphere            pH-sensitive microspheres using Eudragit P4135F                                                                      Low-molecular-weight heparins (LMWH)                              A double emulsion technique with either solvent extraction or evaporation   Exhibited a particle size adapted to the needs of inflammatory bowel disease therapy, an efficient LMWH encapsulation, and a pH-controlled drug release                \[[@B64-molecules-23-01622]\]
  Microparticle          Poly-ε-caprolactone (PCL) celecoxib-loaded microparticles                                                            Celecoxib                                                         Solvent-diffusion technique                                                 Enhanced the bioavailability and extended the duration of drug-plasma concentration in rats                                                                            \[[@B65-molecules-23-01622]\]
